An Overview on Promising Nanotechnological Approaches for the Treatment of Psoriasis

Author(s): Kalpana Pandey, Nimisha*

Journal Name: Recent Patents on Nanotechnology

Volume 14 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Psoriasis is a chronic autoimmune disorder of the skin which is characterized by the reoccurring episodes of inflammatory lesions with a worldwide occurrence of around 2-5%. Psoriasis can be categorized as mild, moderate and severe conditions. In mild psoriasis, there is the formation of rashes, and when it becomes moderate, the skin turns scaly. In severe conditions, the red patches can be seen on the skin surface and the skin becomes itchy. The different treatment approaches include phototherapy, topical, oral and other systemic drug deliveries. Dermal treatment is now highly endorsed in topical indications for psoriatic patients, due to its higher penetration which can be achieved using pharmaceutical carriers.

Objective: Though various conventional formulations are there, therapeutic benefits can be provided only to a limited extent. The objective of this review was to highlight newer biocompatible and biodegradable materials like phospholipids, and forefront drug delivery methods like liposomes, microemulsions, nanoemulsions, niosomes, ethosomes, etc. which has increased the possibility to improve the efficacy and safety of the topical products. Apart from this, many medicinal plants are available in nature that are used for treating skin diseases like psoriasis.

Conclusion: The new trends in nanotechnology are marked by subsequent changes in the pharmaceutical research field. To safeguard the research works in the research field, various patents have been introduced, such as Glaxo Smith Kline (GSK 2981278) – RORγ antagonist, etc. The causes, pathophysiology and the herbal plants that are used in treating the disease are also discussed.

Keywords: Psoriasis, conventional, phototherapy, liposome, ethosome, hyperproliferation.

[1]
Wang Z, Zheng H, Zhou H, et al. Systematic screening and identification of novel psoriasis-specific genes from the transcriptome of psoriasis-like keratinocytes. Mol Med Rep 2019; 19(3): 1529-42.
[PMID: 30592269]
[2]
Rajitha P, Shammika P, Aishwarya S, Gopikrishnan A, Jayakumar R, Sabitha M. Chaulmoogra oil based methotrexate loaded topical nanoemulsion for the treatment of psoriasis. J Drug Deliv Sci Technol 2019; 49: 463-76.
[http://dx.doi.org/10.1016/j.jddst.2018.12.020]
[3]
Katare OP, Raza K, Singh B, Dogra S. Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors. Indian J Dermatol Venereol Leprol 2010; 76(6): 612-21.
[http://dx.doi.org/10.4103/0378-6323.72451] [PMID: 21079304]
[4]
women’s health illness and disabilities-psoriasis; natural lifestyle advisor) 2010 (accessed 5 april 2016).
[5]
Lewis DJ, Chan WH, Hinojosa T, Hsu S, Feldman SR. Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: A review. Clin Dermatol 2019; 37(2): 160-6.
[http://dx.doi.org/10.1016/j.clindermatol.2019.01.011] [PMID: 30981296]
[6]
Daniel J, Roach P, Hartmann J. 978-3-12 (accessed 5 april 2016).
[7]
Kuchekar AB, Pujari RR, Kuchekar SB, Dhole SN, Mule PM. Psoriasis: A comprehensive review. int j pharm life sci 2011; 2(6)
[8]
Victor FC, Gottlieb AB. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol 2002; 1(3): 264-75.
[PMID: 12851985]
[9]
Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64(Suppl. 2): ii37-9.
[http://dx.doi.org/10.1136/ard.2004.030775] [PMID: 15708933]
[10]
Kawamura A, Ochiai T. Candesartan cilexetil induced pustular psoriasis. Eur J Dermatol 2003; 13(4): 406-7.
[PMID: 12948927]
[11]
Steckelings UM, Artuc M, Wollschläger T, Wiehstutz S, Henz BM. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol 2001; 81(5): 321-5.
[http://dx.doi.org/10.1080/000155501317140007] [PMID: 11800136]
[12]
Shan Y. Treatment and management of psoriasis. Prim Health Care 2016; 26(3): 32-41.
[13]
Vincent N, Ramya DD, Vedha HB. Progress in psoriasis therapy via novel drug delivery systems. Dermatol Rep 2014; 6(1): 5451.
[http://dx.doi.org/10.4081/dr.2014.5451] [PMID: 25386329]
[14]
Thaker SJ, Mehta DS, Shah HA, Dave JN, Mundhava SG. A comparative randomized open label study to evaluate. Indian Dermatol Online J 2010; 1(1): 8-9.
[15]
Krueger JG, Bowcock A. Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis 2005; 64(Suppl. 2): ii30-6.
[http://dx.doi.org/10.1136/ard.2004.031120] [PMID: 15708932]
[16]
La Mantia L, Capsoni F. Psoriasis during interferon beta treatment for multiple sclerosis. Neurol Sci 2010; 31(3): 337-9.
[http://dx.doi.org/10.1007/s10072-009-0184-x] [PMID: 19924503]
[17]
Lassus A. A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter’s disease. Curr Med Res Opin 1976; 4(1): 65-9.
[http://dx.doi.org/10.1185/03007997609109283] [PMID: 770082]
[18]
Fierlbeck G, Rassner G. Treatment of psoriasis and psoriatic arthritis with interferon gamma. J Invest Dermatol 1990; 95(6)(Suppl.): 138S-41S.
[http://dx.doi.org/10.1111/1523-1747.ep12875040] [PMID: 2124243]
[19]
Elder JT, Nair RP, Guo SW, Henseler T, Christophers E, Voorhees JJ. The genetics of psoriasis. Arch Dermatol 1994; 130(2): 216-24.
[http://dx.doi.org/10.1001/archderm.1994.01690020082014] [PMID: 8304761]
[20]
Mahajan R, Handa S. Pathophysiology of psoriasis. Indian J Dermatol Venereol Leprol 2013; 79(7)(Suppl. 7): S1-9.
[http://dx.doi.org/10.4103/0378-6323.115505] [PMID: 23974689]
[21]
Langley RG. Effective and sustainable biologic treatment of psoriasis: What can we learn from new clinical data? J Eur Acad Dermatol Venereol 2012; 26(Suppl. 2): 21-9.
[http://dx.doi.org/10.1111/j.1468-3083.2011.04412.x] [PMID: 22356632]
[22]
Raghuwanshi N, Yadav TC, Srivastava AK, Raj U, Varadwaj P, Pruthi V. Structure-based drug designing and identification of Woodfordia fruticosa inhibitors targeted against heat shock protein (HSP70-1) as suppressor for Imiquimod-induced psoriasis like skin inflammation in mice model. Mater Sci Eng C 2019; 95: 57-71.
[http://dx.doi.org/10.1016/j.msec.2018.10.061] [PMID: 30573271]
[23]
Nestle FO, Zheng XG, Thompson CB, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J Immunol 1993; 151(11): 6535-45.
[PMID: 7504023]
[24]
Johnson-Huang LM, Lowes MA, Krueger JG. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech 2012; 5(4): 423-33.
[http://dx.doi.org/10.1242/dmm.009092] [PMID: 22730473]
[25]
Gall JS, Kalb RE. Infliximab for the treatment of plaque psoriasis. Biologics 2008; 2(1): 115-24.
[PMID: 19707434]
[26]
Powles AV, Griffiths CE, Seifert MH, Fry L. Exacerbation of psoriasis by indomethacin. Br J Dermatol 1987; 117(6): 799-800.
[http://dx.doi.org/10.1111/j.1365-2133.1987.tb07364.x] [PMID: 3426958]
[27]
Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56(1): 31.e1-31.e15.
[http://dx.doi.org/10.1016/j.jaad.2006.07.017] [PMID: 17097378]
[28]
Skerritt PW. Psoriatic arthritis during lithium therapy. Aust N Z J Psychiatry 1987; 21(4): 601-4.
[http://dx.doi.org/10.3109/00048678709158929] [PMID: 3130043]
[29]
Murphy EC, Schaffter SW, Friedman AJ. Nanotechnology for psoriasis therapy. Curr Dermatol Rep 2019; 8(1): 14-25.
[30]
Rudolph RI. Lithium-induced psoriasis of the fingernails. J Am Acad Dermatol 1992; 26(1): 135-6.
[http://dx.doi.org/10.1016/S0190-9622(08)80533-6] [PMID: 1732326]
[31]
Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of psoriasis
[32]
Farahnik B, Beroukhim K, Abrouk M, et al. A review of phase III trials. Dermatol Ther (Heidelb) 2016; 6(2): 111-24.
[http://dx.doi.org/10.1007/s13555-016-0121-x] [PMID: 27221323]
[34]
Mrowietz U, Kragballe K, Nast A, Reich K. Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting. J Eur Acad Dermatol Venereol 2011; 25(Suppl. 3): 1-13.
[http://dx.doi.org/10.1111/j.1468-3083.2011.04033.x] [PMID: 21470314]
[35]
Davison NJ, Warren RB, Mason KJ, et al. Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. Br J Dermatol 2017; 177(3): 828-36.
[http://dx.doi.org/10.1111/bjd.15551] [PMID: 28386916]
[36]
Sun J, Zhao Y, Hu J. Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. PLoS One 2013; 8(6): e67078.
[http://dx.doi.org/10.1371/journal.pone.0067078] [PMID: 23825622]
[37]
Morganti P, Ruocco E, Wolf R, Ruocco V. Percutaneous absorption and delivery systems. Clin Dermatol 2001; 19(4): 489-501.
[http://dx.doi.org/10.1016/S0738-081X(01)00183-3] [PMID: 11535394]
[38]
Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15: 749-95.
[http://dx.doi.org/10.1146/annurev.immunol.15.1.749] [PMID: 9143706]
[39]
Rahman M, Akhter S, Ahmad J. nano medicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy. epert opinion on drug delivery 2015; 312(4): 635-52.
[40]
Patel R, Singh SK, Singh S, Sheth NR, Gendle R. Development and characterization of curcumin loaded transfersome for transdermal delivery. journal of pharmaceutical sciences and research 2009; 11(4): 71.
[41]
Benson HA. Transdermal drug delivery: Penetration enhancement techniques. Curr Drug Deliv 2005; 2(1): 23-33.
[http://dx.doi.org/10.2174/1567201052772915] [PMID: 16305405]
[42]
2. Zhang H, Zhai Y, Wang J, Zhai G. New progress and prospects: The application of nanogel in drug delivery. Mater Sci Eng C 2016; 60: 560-8.
[http://dx.doi.org/10.1016/j.msec.2015.11.041]
[43]
Panonnummal R, Jayakumar R, Sabitha M. Comparative anti-psoriatic efficacy studies of clobetasol loaded chitin nanogel and marketed cream. Eur J Pharm Sci 2017; 96: 193-206.
[http://dx.doi.org/10.1016/j.ejps.2016.09.007] [PMID: 27615594]
[44]
Divya G, Panonnummal R, Gupta S, Jayakumar R, Sabitha M. Acitretin and aloe-emodin loaded chitin nanogel for the treatment of psoriasis. Eur J Pharm Biopharm 2016; 107: 97-109.
[http://dx.doi.org/10.1016/j.ejpb.2016.06.019] [PMID: 27368748]
[45]
Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release 2007; 123(2): 148-54.
[http://dx.doi.org/10.1016/j.jconrel.2007.08.005] [PMID: 17884226]
[46]
Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater 2016; 1(12): 16071.
[http://dx.doi.org/10.1038/natrevmats.2016.71] [PMID: 29657852]
[47]
Srikanth K, Rama Mohan Gupta V, Manvi SR. Particulate carrier systems: a review. int res j pharm 2012. 3(110: 22-6.
[48]
Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003; 102(1): 161-8.
[http://dx.doi.org/10.1182/blood-2002-12-3793] [PMID: 12649136]
[49]
Behera J, Keservani RK, Yadav A, Tripathi M, Chadoker A. Methoxsalen loaded chitosan coated microemulsion for effective treatment of psoriasis. Int J Drug Deliv 2010; 2(2): 159-67.
[http://dx.doi.org/10.5138/ijdd.2010.0975.0215.02025]
[50]
Baroli B, López-Quintela MA, Delgado-Charro MB, Fadda AM, Blanco-Méndez J. Microemulsions for topical delivery of 8-methoxsalen. J Control Release 2000; 69(1): 209-18.
[http://dx.doi.org/10.1016/S0168-3659(00)00309-6] [PMID: 11018558]
[51]
Amarji B, Garg NK, Singh B, Katare OP. Microemulsions mediated effective delivery of methotrexate hydrogel: More than a tour de force in psoriasis therapeutics. J Drug Target 2016; 24(2): 147-60.
[http://dx.doi.org/10.3109/1061186X.2015.1058804] [PMID: 26204326]
[52]
Halnor VV, Pande VV, Borawake DD, Nagare HS. Nanoemulsion: A novel platform for drug delivery system. J Mat Sci Nanotechol 2018; 6(1): 104.
[53]
Sieber S, Grossen P, Uhi P, et al. Zebrafish as a predictive screening model to assess macrophage clearance of liposomes in vivo. Nanomedicine 2019; 17: 82-93.
[54]
Walunj M, Doppalapudi S, Bulbake U, Khan W. Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis. J Liposome Res 2019; 30(1): 68-79.
[http://dx.doi.org/10.1080/08982104.2019.1593449] [PMID: 30897993]
[55]
Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm 2001; 228(1-2): 43-52.
[http://dx.doi.org/10.1016/S0378-5173(01)00810-9] [PMID: 11576767]
[56]
Wadhwa S, Singh B, Sharma G, Raza K, Katare OP. Liposomal fusidic acid as a potential delivery system: A new paradigm in the treatment of chronic plaque psoriasis. Drug Deliv 2016; 23(4): 1204-13.
[http://dx.doi.org/10.3109/10717544.2015.1110845] [PMID: 26592918]
[57]
Srisuk P, Thongnopnua P, Raktanonchai U, Kanokpanont S. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment. Int J Pharm 2012; 427(2): 426-34.
[http://dx.doi.org/10.1016/j.ijpharm.2012.01.045] [PMID: 22310459]
[58]
Avramoff A, Khan W, Ezra A, Elgart A, Hoffman A, Domb AJ. Cyclosporin pro-dispersion liposphere formulation. J Control Release 2012; 160(2): 401-6.
[http://dx.doi.org/10.1016/j.jconrel.2011.12.016] [PMID: 22227025]
[59]
Abdulbaqi IM, Darwis Y, Khan NA, Assi RA, Khan AA. Ethosomal nanocarriers: The impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials. Int J Nanomedicine 2016; 11: 2279-304.
[http://dx.doi.org/10.2147/IJN.S105016] [PMID: 27307730]
[60]
Avasatthi V, Pawar H, Dora CP, Bansod P, Gill MS, Suresh S. A novel nanogel formulation of methotrexate for topical treatment of psoriasis: optimization, in vitro and in vivo evaluation. Pharm Dev Technol 2016; 21(5): 554-62.
[PMID: 26024238]
[61]
Korade S, Deshmukh MT, Shete RV. Formulation and evaluation of ethosomal gel containing clobetasol J Eur Pharm Med Res 2016; 3: 664-72.
[62]
Garg A. herbal nanotherapeutics: a noval approach for herbal drug delivery system. j med pharm allied sci 2016; 201(10): 1.
[63]
Jain S, Jain AK, Pohekar M, Thanki K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity. Free Radic Biol Med 2013; 65: 117-30.
[http://dx.doi.org/10.1016/j.freeradbiomed.2013.05.041] [PMID: 23792276]
[64]
Yu H, Huang Q. Improving the oral bioavailability of curcumin using novel organogel-based nanoemulsions. J Agric Food Chem 2012; 60(21): 5373-9.
[http://dx.doi.org/10.1021/jf300609p] [PMID: 22506728]
[65]
Syed TA, Ahmad SA, Holt AH, Ahmad SA, Ahmad SH, Afzal M. Management of psoriasis with Aloe vera extract in a hydrophilic cream: A placebo-controlled, double-blind study. Trop Med Int Health 1996; 1(4): 505-9.
[http://dx.doi.org/10.1046/j.1365-3156.1996.d01-91.x] [PMID: 8765459]
[66]
Horvath F. therapeutical compositions against psoriasis. us patent 5165932 1992.
[67]
Joe B, Lokesh BR. Effect of curcumin and capsaicin on arachidonic acid metabolism and lysosomal enzyme secretion by rat peritoneal macrophages. Lipids 1997; 32(11): 1173-80.
[http://dx.doi.org/10.1007/s11745-997-0151-8] [PMID: 9397403]
[68]
Al Jassir MS. Chemical composition and microflora of black cumin (Nigella sativa L.) seeds growing in Saudi Arabia. Food Chem 1992; 45: 239-42.
[http://dx.doi.org/10.1016/0308-8146(92)90153-S]
[69]
Saelee C, Thongrakard V, Tencomnao T. Effects of Thai medicinal herb extracts with anti-psoriatic activity on the expression on NF-κB signaling biomarkers in HaCaT keratinocytes. Molecules 2011; 16(5): 3908-32.
[http://dx.doi.org/10.3390/molecules16053908] [PMID: 21555979]
[70]
Shrivastava S, Sindhu KR, Kumar S, Kumar S, Kumar P. Antipsoriatic and phytochemical evaluation of Thespesiapopulnea bark extracts. Int J Pharma Sci 2009; 1: 176-85.
[71]
Aghmiuni AI, Khiavi AA. Medicinal plants to calm and treat psoriasis disease. Aromatic and medicinal plants- back to nature. IntechOpen London 2017.
[http://dx.doi.org/10.5772/67062]
[72]
Cellzome Ltd. heterocyclyl pyrimidine analogs as tyk2 inhibitors. us 9296725,
[73]
Roche AG. thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors. wo patent 2015091584, 2015.
[74]
Puglia C, Damiani E, Offerta A, et al. Evaluation of Nanostructured Lipid Carriers (NLC) and nanoemulsions as carriers for UV-filters: characterization, in vitro penetration and photostability studies. Eur J Pharm Sci 2014; 51(151): 211-7.
[http://dx.doi.org/10.1016/j.ejps.2013.09.023] [PMID: 24157543]
[75]
Gupta V, Barupal AK, Ramteke S. Formulation development and in vitro characterization of proliposomes for topical delivery of aceclofenac. Indian J Pharm Sci 2008; 70(6): 768-75.
[http://dx.doi.org/10.4103/0250-474X.49119] [PMID: 21369438]
[76]
Takeda Pharmaceutical Company Ltd. heterocyclic com-pound. wo2015016206.,, (*excellent tyk2 inhibitory effect)
[77]
Lakshimi N. tyk2 inhibitors and uses thereof. wo patent 2015131080 2015.
[78]
Leonardi CL, Powers JL, Matheson RT, et al. Etanercept Psoriasis Study Group Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349(21): 2014-22.
[http://dx.doi.org/10.1056/NEJMoa030409] [PMID: 14627786]
[79]
Shaw MH, Boyartchuk V, Wong S, et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci USA 2003; 100(20): 11594-9.
[http://dx.doi.org/10.1073/pnas.1930781100] [PMID: 14500783]
[80]
Study of Safety and Efficacy of Topical GSK2981278 – Cli-nical Trials.gov.available from: https://clinicaltrials.gov/ct2/show/NCT02548052 [accessed 5 april 2016].
[81]
Research programme: autoimmune disorder therapies 2010 [accessed 5 april 2016].
[82]
Arrien pharmaceuticals – adis insight [accessed 5 april 2016].
[83]
vitae pharma – pipeline. available from: http://vitaepharma.com/pipeline/[last accessed 10 may 2016]
[84]
Korting HC, Blecher P, Schäfer-Korting M, Wendel A. Topical liposome drugs to come: what the patent literature tells us. A review. J Am Acad Dermatol 1991; 25(6 Pt 1): 1068-71.
[http://dx.doi.org/10.1016/0190-9622(91)70309-P] [PMID: 1810984]
[85]
Battaglia L, Ugazio E. Lipid Nano-and microparticles: An overview of patent-related research. J Nanomater 2019.
[http://dx.doi.org/10.1155/2019/2834941]
[86]
Sandborn WJ, Ghosh S, Panes J, et al. Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367(7): 616-24.
[http://dx.doi.org/10.1056/NEJMoa1112168] [PMID: 22894574]
[87]
concert pharmaceuticals inc. deuterated derivatives of ruxo-litinib wo patent 20131887831, 2013.
[88]
Chiricozzi A, Saraceno R, Novelli L, et al. Small molecules and antibodies for the treatment of psoriasis: A patent review (2010-2015). Expert Opin Ther Pat 2016; 26(7): 757-66.
[http://dx.doi.org/10.1080/13543776.2016.1192129] [PMID: 27266423]
[89]
Schafer PH, Gandhi A, Capone L. inventors; celgene c. methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases. us patent us patent 9272035, 2016.
[90]
Kakar R, Rao R, Goswami A, Nanda S, Saroha K. Proniosomes: An emerging vesicular system in drug delivery and cosmetics. Der Pharmacia Lettre 2010; 2(4): 227-39.
[91]
Wagner A, Vorauer-Uhl K. liposome technology for industrial purposes. j drug deliv 2011 2011.
[92]
Carrer DC, Higa LH, Tesoriero MV, Morilla MJ, Roncaglia DI, Romero EL. Structural features of ultradeformable archaeosomes for topical delivery of ovalbumin. Colloids Surf B Biointerfaces 2014; 121(148): 281-9.
[http://dx.doi.org/10.1016/j.colsurfb.2014.05.015] [PMID: 24974012]
[93]
Kulkarni M, Breen A, Greiser U, O’Brien T, Pandit A. Fibrin-lipoplex system for controlled topical delivery of multiple genes. Biomacromolecules 2009; 10(6): 1650-4.
[http://dx.doi.org/10.1021/bm900248n] [PMID: 19385658]
[94]
Han S, Shen JQ, Gan Y, et al. Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin 2010; 31(8): 990-8.
[http://dx.doi.org/10.1038/aps.2010.98] [PMID: 20686524]
[95]
Mittal R, Sharma A, Arora S. Ufasomes mediated cutaneous delivery of dexamethasone: Formulation and evaluation of anti-inflammatory activity by carrageenininduced rat paw edema model. J Pharm 2013; 2013: 680580.
[http://dx.doi.org/10.1155/2013/680580] [PMID: 26555990]
[96]
Manosroi J, Khositsuntiwong N, Manosroi W, Götz F, Werner RG, Manosroi A. Enhancement of transdermal absorption, gene expression and stability of tyrosinase plasmid (pMEL34)-loaded elastic cationic niosomes: Potential application in vitiligo treatment. J Pharm Sci 2010; 99(8): 3533-41.
[http://dx.doi.org/10.1002/jps.22104] [PMID: 20213835]
[97]
Bos JD, Spuls PI. Topical treatments in psoriasis: today and tomorrow. clin dermatol 2008; 26(5): 432-7.
[http://dx.doi.org/10.1016/j.clindermatol.2007.10.025] [PMID: 18755361]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 2
Year: 2020
Published on: 16 September, 2020
Page: [102 - 118]
Pages: 17
DOI: 10.2174/1872210514666200204124130
Price: $65

Article Metrics

PDF: 19
HTML: 1